MX339840B - Moduladores de los receptores de 5-ht y metodos de uso de los mismos. - Google Patents

Moduladores de los receptores de 5-ht y metodos de uso de los mismos.

Info

Publication number
MX339840B
MX339840B MX2012013536A MX2012013536A MX339840B MX 339840 B MX339840 B MX 339840B MX 2012013536 A MX2012013536 A MX 2012013536A MX 2012013536 A MX2012013536 A MX 2012013536A MX 339840 B MX339840 B MX 339840B
Authority
MX
Mexico
Prior art keywords
methods
compounds
modulators
receptors
compositions
Prior art date
Application number
MX2012013536A
Other languages
English (en)
Other versions
MX2012013536A (es
Inventor
C Turner Sean
F Gasiecki Alan
Braje Wilfried
Zhang Min
W Djuric Stevan
Gandarilla Jorge
Shekhar Shashank
Relo Ana-Lucia
S Welch Dennie
W Kruger Albert
Zhao Hongyu
Li Huanqiu
M Thompson Christina
Akritopoulou-Zanze Irini
s wilson Noel
Original Assignee
Abbvie Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/784,624 external-priority patent/US9187483B2/en
Application filed by Abbvie Inc * filed Critical Abbvie Inc *
Publication of MX2012013536A publication Critical patent/MX2012013536A/es
Publication of MX339840B publication Critical patent/MX339840B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)

Abstract

La presente solicitud se refiere a derivados de decahidropirroloazepina, octahidro-oxepinopirrol, dióxido de octahidropirrolotiazepina, decahidrociclohepta[c]pirrol fusionados a arilo y heteroarilo, y derivados de octahidrociclohepta[c]pirrol de la fórmula (I) en la cual R1, R2, R3, R4, R5, A, Y1, Y2, y Y3 son como se definen en la descripción. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, a procedimientos para elaborar dichos compuestos, y a métodos para tratar condiciones patológicas utilizando dichos compuestos y composiciones, y a métodos para identificar dichos compuestos.
MX2012013536A 2010-05-21 2010-11-19 Moduladores de los receptores de 5-ht y metodos de uso de los mismos. MX339840B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/784,624 US9187483B2 (en) 2009-05-22 2010-05-21 Modulators of 5-HT receptors and methods of use thereof
US12/950,029 US8846951B2 (en) 2009-05-22 2010-11-19 Modulators of 5-HT receptors and methods of use thereof
PCT/US2010/057454 WO2011146089A1 (en) 2010-05-21 2010-11-19 Modulators of 5-ht receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012013536A MX2012013536A (es) 2013-06-28
MX339840B true MX339840B (es) 2016-06-14

Family

ID=44991967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013536A MX339840B (es) 2010-05-21 2010-11-19 Moduladores de los receptores de 5-ht y metodos de uso de los mismos.

Country Status (14)

Country Link
US (1) US8846951B2 (es)
EP (1) EP2571353B1 (es)
JP (1) JP5996528B2 (es)
KR (1) KR101770979B1 (es)
CN (2) CN103002735B (es)
AU (1) AU2010353724B2 (es)
BR (1) BR112012030534A2 (es)
CA (1) CA2800161C (es)
IL (1) IL223392A (es)
MX (1) MX339840B (es)
NZ (1) NZ603792A (es)
RU (2) RU2567751C2 (es)
SG (1) SG185672A1 (es)
WO (1) WO2011146089A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116282A2 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nicotinic acetylcholine receptor agonists
WO2013187069A1 (ja) * 2012-06-15 2013-12-19 国立大学法人金沢大学 Ｐｄｔ効果増強剤
CN102796044A (zh) * 2012-08-24 2012-11-28 南通大学 2,3,4,5-四氢-1h-2-苯并氮杂卓-1-酮衍生物的化学合成方法
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
KR102558540B1 (ko) 2016-08-30 2023-07-21 테트라페이즈 파마슈티컬스, 인코포레이티드 테트라사이클린 화합물 및 치료 방법
EP3608314A4 (en) 2017-03-13 2020-12-30 Sumitomo Dainippon Pharma Co., Ltd. 2,6-DISUBSTITUTED PYRIDINE DERIVATIVE
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法
WO2021101854A1 (en) 2019-11-19 2021-05-27 Trevena, Inc. Compounds and methods of preparing compounds s1p1 modulators
CN111423410B (zh) * 2020-05-11 2022-11-15 无锡贝塔医药科技有限公司 一种稳定性同位素13c标记1,4-二硫-2，5-二醇的合成方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350814A (en) * 1979-10-22 1982-09-21 Ici Americas Inc. Pyrrolo [3,4-c]quinoline compounds
US4268513A (en) * 1979-10-22 1981-05-19 Ici Americas Inc. Pyrrolo [3,4-c]quinoline compounds and pharmaceutical compositions, methods for their use and preparation
US4440768A (en) * 1981-01-08 1984-04-03 Ici Americas Inc. Hexahydropyrrolo[3,4-c]quinoline compounds and pharmaceutical compositions, and methods for their use
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
KR910700251A (ko) 1988-12-15 1991-03-14 원본미기재 5-ht 선택제
US5387590A (en) 1989-08-30 1995-02-07 Pfizer Inc. Benzazabicyclic carbamates as novel cholinesterase inhibitors
FI950842A0 (fi) 1992-08-24 1995-02-23 Merrell Dow Pharma Enkefalinaasin inhibiittoreina käyttökelpoisia uusia 2-substituoituja trisyklisiä indaani-2-merkaptoasetyyliamidijohdannaisia
US5317017A (en) * 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5597922A (en) 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
WO1996038435A1 (en) 1995-05-30 1996-12-05 Abbott Laboratories Dopamine agonists
JPH09221475A (ja) 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
AU2657499A (en) 1998-02-04 1999-08-23 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
US6649366B2 (en) 1999-12-29 2003-11-18 Smithkline Beecham Corporation Methods and compositions related to modulators of annexin and cartilage homeostasis
EP1406631A4 (en) 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
KR20060052867A (ko) * 2003-07-23 2006-05-19 엑셀리시스, 인코포레이티드 약제로서의 아제핀 유도체
KR100601641B1 (ko) * 2003-08-08 2006-07-14 삼성전자주식회사 비피리딘계 금속 착화합물 및 이를 포함하는 잉크 조성물
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
CN1980710B (zh) * 2004-06-30 2013-06-12 阿特西斯公司 作为5-羟色胺受体调节剂的取代的氮杂环庚烯衍生物
US7618980B2 (en) * 2004-07-14 2009-11-17 Bristol-Myers Squibb Company Pyrrolo(oxo)quinolines as 5HT ligands
US7572805B2 (en) * 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
AU2005318596B2 (en) * 2004-12-21 2010-12-23 F. Hoffmann-La Roche Ag Chroman derivatives and their use as 5-HT receptor ligands
RS50997B (sr) * 2004-12-23 2010-10-31 Arena Pharmaceuticals Inc. Kompozicije 5ht2c receptor modulatora i postupci njihove upotrebe
JP2009501705A (ja) * 2005-07-05 2009-01-22 アストラゼネカ・アクチエボラーグ 新規化合物、その製造方法、中間体、医薬組成物、並びにアルツハイマー病、認知障害、統合失調症に伴う認識機能障害、肥満及びパーキンソン病のような５−ｈｔ６介在疾患の治療におけるそれらの使用
JP2009501176A (ja) 2005-07-12 2009-01-15 アボット ゲーエムベーハー ウント カンパニー カーゲー グリコーゲンシンターゼキナーゼ３阻害薬としてのピリダジン化合物
AU2006276096A1 (en) 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
KR101353268B1 (ko) * 2005-08-04 2014-02-06 얀센 파마슈티카 엔.브이. 세로토닌 수용체 모듈레이터로서의 피리미딘 화합물
GB0517292D0 (en) 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds
NZ565536A (en) * 2005-08-31 2011-03-31 Hoffmann La Roche Pyrazolone derivatives as 11-beta HSD1 inhibitors
WO2007053725A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2007067781A2 (en) 2005-12-08 2007-06-14 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
AR060324A1 (es) * 2006-03-24 2008-06-11 Wyeth Corp Metodos para modular la funcion de la vejiga
JP2009531434A (ja) * 2006-03-24 2009-09-03 ワイス 痛みの治療
CN101616919B (zh) * 2006-12-28 2012-10-10 雅培制药有限公司 聚（adp核糖）聚合酶抑制剂
TW200924752A (en) * 2007-09-17 2009-06-16 Organon Nv Tricyclic heterocyclic derivatives
MX2010010235A (es) 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
NZ618902A (en) * 2009-05-22 2015-06-26 Abbvie Inc Modulators of 5-ht receptors and methods of use thereof

Also Published As

Publication number Publication date
RU2567751C2 (ru) 2015-11-10
US8846951B2 (en) 2014-09-30
CA2800161C (en) 2017-12-12
RU2012155694A (ru) 2014-06-27
BR112012030534A2 (pt) 2015-09-29
CN103002735A (zh) 2013-03-27
RU2015140748A (ru) 2018-12-26
JP5996528B2 (ja) 2016-09-21
KR20130097089A (ko) 2013-09-02
JP2013526618A (ja) 2013-06-24
CN103002735B (zh) 2015-05-20
AU2010353724B2 (en) 2015-02-12
EP2571353A1 (en) 2013-03-27
MX2012013536A (es) 2013-06-28
EP2571353A4 (en) 2014-01-22
CA2800161A1 (en) 2011-11-24
SG185672A1 (en) 2013-01-30
NZ603792A (en) 2015-07-31
EP2571353B1 (en) 2017-08-09
WO2011146089A1 (en) 2011-11-24
KR101770979B1 (ko) 2017-08-24
CN104860951A (zh) 2015-08-26
US20110118231A1 (en) 2011-05-19
IL223392A (en) 2017-01-31
AU2010353724A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
MX339840B (es) Moduladores de los receptores de 5-ht y metodos de uso de los mismos.
WO2010003133A3 (en) Cdk modulators
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
EA201100666A1 (ru) Тиоамидные соединения, способ их получения и способ их применения
MX2009012082A (es) Compuestos de ariloazol-2-il cianoetilamino, metodo para prepararlos y metodo para utilizarlos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MY163216A (en) Compositions and methods for modulating fxr
MX2011012479A (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
MY153057A (en) Tryclic compounds,compositions and methods
TNSN08311A1 (en) Indole sulfonamide modulators of progesterone receptors
EA201070605A8 (ru) Применение бактерий для производства биоэнергии
MX2013012211A (es) Derivados biciclicos substituidos de metil amina como moduladores de receptores de esfingosina-1-fosfato.
MY154962A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
IN2012DN05125A (es)
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CA2818986A1 (en) Indole derivatives as modulators of s1p receptors
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
WO2014121055A3 (en) Flap modulators
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: ABBVIE INC.*

FG Grant or registration